Stockreport

ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

ARCA biopharma, Inc.  (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
PDF FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure [Read more]